Get started

Financials · BFRI

Biofrontera Inc. (BFRI) financials

For the twelve months ended Jun 30, 2026, Biofrontera Inc. reported $46.17M of revenue and -$6.37M of net income.

Revenue, TTM
$46.17M
Revenue growth, YoY
+17.8%
Net income, TTM
-$6.37M
Net margin
-13.8%
Free cash flow, TTM
-$7.93M
EPS, diluted, TTM
-$0.46
Cash
$4.66M
P/S
0.27
Market cap
$12.3M
Annual revenue$41.70M
FY2020FY2025
Annual net income-$10.54M
FY2020FY2025
Annual free cash flow-$13.36M
FY2022FY2025

BFRI revenue and earnings growth

BFRI revenueQ2 2026$12.00M

Quarter YoY
+32.9%
QoQ
+19.0%
FY YoY
+11.7%
5Y CAGR
+17.2%

BFRI revenue was $12.00M in fiscal Q2 2026 (ended Jun 30, 2026), up 32.9% from a year earlier and up 19.0% from the prior quarter. For the full fiscal 2025 it was $41.70M, up 11.7% from fiscal 2024. Compound annual growth was +17.2% over 5 years. It rose in each of the last 5 fiscal years. Fiscal 2025 is the highest of the 6 fiscal years on file.

BFRI net incomeQ2 2026-$604.0K

BFRI net income was -$604.0K in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$5.32M a year earlier. For the full fiscal 2025 it was -$10.54M, compared with -$17.76M in fiscal 2024.

BFRI EPSQ2 2026-$0.05

BFRI diluted EPS was -$0.05 in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$0.57 a year earlier. For the full fiscal 2025 it was -$1.04.

BFRI free cash flowQ2 2026-$1.66M

BFRI free cash flow was -$1.66M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$3.05M a year earlier. For the full fiscal 2025 it was -$13.36M, compared with -$10.28M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
Revenue$41.70M$37.32M$34.07M$28.67M$24.10M$18.85M
Research and development$3.72M$2.09M$77.0K---
Selling, general and admin$37.75M$33.79M$18.49M$35.14M$36.51M$17.71M
Operating income-$11.35M-$17.21M-$22.68M-$18.58M-$25.20M-$9.61M
Interest expense--$220.0K$12.0K$344.0K$2.87M
Pre-tax income-$10.51M-$17.74M-$20.12M-$608.0K-$37.66M-$10.92M
Income tax$25.0K$22.0K$14.0K$32.0K$56.0K$64.0K
Net income-$10.54M-$17.76M-$20.13M-$640.0K-$37.71M-$10.99M
EPS, basic-$1.04-$3.22-$13.02-$0.61-$85.60-$9589.60
EPS, diluted-$1.04-$3.22-$13.02-$0.61-$85.60-$9589.60
Diluted shares10.2M5.5M1.5M1.1M440.4M1.1M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
Cash and equivalents$6.39M$5.91M$1.34M$17.21M$24.55M$8.08M
Receivables$7.29M-----
Inventory$1.43M$6.65M$10.91M$7.17M$4.46M$7.09M
Current assets$18.08M$20.70M$23.07M$43.14M$46.42M$19.58M
Total assets$28.56M$22.10M$27.93M$50.88M$53.22M$24.14M
Current liabilities$11.89M$12.02M$18.09M$20.89M$13.84M$4.42M
Short-term debt--$3.90M---
Total liabilities$18.08M$17.67M$23.14M$27.01M$41.88M$18.31M
Shareholders' equity$10.48M$4.43M$4.79M$23.88M$11.34M$5.83M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
Operating cash flow-$13.36M-$10.27M-$24.89M-$16.20M-$26.71M-$12.37M
Capital expenditures$2.0K$10.0K$5.0K$38.0K--
Free cash flow-$13.36M-$10.28M-$24.90M-$16.24M--
Investing cash flow$3.00M-$3.0K$619.0K-$5.16M-$11.0K-
Financing cash flow$10.85M$14.84M$8.41M$14.02M$43.19M$13.19M
Stock-based compensation$951.0K$1.02M$1.04M$1.85M$129.0K-
Depreciation and amortization$138.0K$421.0K$600.0K---

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
Revenue growth, YoY11.7%9.5%18.8%19.0%27.9%-
Operating margin-27.2%-46.1%-66.6%-64.8%-104.6%-51.0%
Net margin-25.3%-47.6%-59.1%-2.2%-156.5%-58.3%
Free cash flow margin-32.0%-27.5%-73.1%-56.6%--
Return on equity-100.5%-400.6%-420.0%-2.7%-332.6%-188.5%
Return on assets-36.9%-80.4%-72.1%-1.3%-70.9%-45.5%
Current ratio1.521.721.282.063.364.43

Source: XBRL data Biofrontera Inc. files with the SEC, latest filing dated Aug 13, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures and share counts are restated for stock splits the filings show: 1-for-20, first reported Aug 11, 2023.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

BFRI peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
BFRI$46.17M+17.8%-$6.37M-13.8%$12.3M
LLY$86.46B+45.5%$27.58B31.9%$1.27T
JNJ$99.33B+7.8%$16.09B16.2%$664.95B
ABBV$66.01B+10.7%$10.34B15.7%$514.92B
MRK$67.38B+4.9%$2.45B3.6%$361.71B
NVS$54.53B+8.4%$13.98B25.6%$310.17B
AZN$58.74B+8.6%$10.22B17.4%$289.10B
ABT$48.23B+10.0%$4.70B9.7%$190.39B
NVODKK 309.06B+6.4%DKK 102.43B33.1%$178.51B

BFRI FAQ

8 questions
  • What is BFRI revenue?
    Biofrontera Inc. (BFRI) reported $46.17M of revenue for the twelve months ended Jun 30, 2026. That is up 17.8% from the year before. Revenue for fiscal 2025 was $41.70M.
  • Is BFRI profitable?
    No. Biofrontera Inc. reported a net loss of $6.37M for the twelve months ended Jun 30, 2026.
  • How much cash and debt does BFRI have?
    Biofrontera Inc. reported $4.66M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is BFRI revenue growing?
    Biofrontera Inc.'s revenue changed +11.7% in fiscal 2025, to $41.70M. Its compound annual growth rate was +17.2% over 5 years.
  • What is BFRI free cash flow?
    Biofrontera Inc. generated -$7.93M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$7.93M less capital expenditures.
  • What is BFRI earnings per share?
    Diluted earnings per share were -$0.46 for the twelve months ended Jun 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did BFRI last report financial results?
    The latest statements here come from Biofrontera Inc.'s 10-Q filed on Aug 13, 2026, covering the period ended Jun 30, 2026.
  • Where does this BFRI financial data come from?
    Quantisnow builds these statements from the structured XBRL data Biofrontera Inc. files with the SEC. It is provided for information only and is not investment advice.